AstraZeneca spins out biotech to focus on autoimmune candidates
AstraZeneca, Viela Bio
0 Comment
AstraZeneca’s biologics division MedImmune is to spin out a new standalone biotech to develop six early-stage inflammation and autoimmunity programmes.